AxoGen sees FY25 revenue growth 15%-17%

The company said, “We expect revenue growth to be in the range of 15% to 17%. In addition, we anticipate gross margin to be in the range of 73% – 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%. Additionally, we expect to be net cash flow positive for the full year.”